Bristol-Myers Squibb

YTD

ALL

Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMY

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies.

CEO

Christopher S. Boerner

CEOChristopher S. Boerner

Employees

32,500

Employees32,500

Headquarters

Princeton, New Jersey

HeadquartersPrinceton, New Jersey

Founded

1933

Founded1933

Employees

32,500

Employees32,500

BMY Key Statistics

Market cap

115.69B

Market cap115.69B

Price-Earnings ratio

15.97

Price-Earnings ratio15.97

Dividend yield

4.39%

Dividend yield4.39%

Average volume

9.12M

Average volume9.12M

High today

$57.33

High today$57.33

Low today

$56.57

Low today$56.57

Open price

$57.02

Open price$57.02

Volume

3.86M

Volume3.86M

52 Week high

$62.89

52 Week high$62.89

52 Week low

$42.52

52 Week low$42.52

Stock Snapshot

Bristol-Myers Squibb(BMY) stock is priced at $56.66, giving the company a market capitalization of 115.69B. It carries a P/E multiple of 15.97 and pays a dividend yield of 4.4%.

During the trading session on 2026-05-29, Bristol-Myers Squibb(BMY) shares reached a daily high of $57.33 and a low of $56.57. At a current price of $56.66, the stock is +0.2% higher than the low and still -1.2% under the high.

Trading activity shows a volume of 3.86M, compared to an average daily volume of 9.12M.

The stock's 52-week range extends from a low of $42.52 to a high of $62.89.

BMY News

TipRanks 46m

Bristol-Myers Squibb Advances MTAP-Targeted Cancer Trial, Laying Groundwork for Long-Term Oncology Upside

Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from...

TipRanks 46m

Bristol-Myers Squibb Backs New Cell Therapy Combo in Early GI Cancer Trial

Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from...

TipRanks 7h

Bristol-Myers Squibb: Hold Rating Reiterated as Analyst Maintains $61 Price Target Amid Near-Term Uncertainties and Long-Term Pipeline Potential

Bristol-Myers Squibb, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Asad Haider from Goldman Sachs maintained a Hold...

Analyst ratings

61%

of 31 ratings

Buy

35.5%

Hold

61.3%

Sell

3.2%

More BMY News

Seeking Alpha 7d

Bristol-Myers Squibb snaps six straight sessions of gains

BMY shares snapped six straight sessions of gains as the stock closed 0.15% lower at $59.46 on Friday. The biopharmaceutical company gained about 5% in the pre...

People also own

Based on the portfolios of people who own BMY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.